Skip to main content
    B

    Biofrontera Inc. Warrants (BFRIW)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.00
    +0.00 (+0.00%)

    Last updated: Nov 02, 2026 at 4:00 PM ET

    Biofrontera Inc. Warrants (BFRIW) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    Biofrontera Inc. Warrants reported revenue of $41.70M for the fiscal year ended Dec 31, 2025, up 11.8% from the year before. That year, net income was -$10.54M with a net margin of -25.3%, operating cash flow was -$13.36M and free cash flow was -$13.36M. The quarter ended Jun 30, 2026 had revenue of $12.00M and net income of -$604.00K.

    Revenue and Margins

    The operating margin was -21.9% in the fiscal year ended Dec 2025, the highest of the 6 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $26.18M, a compound annual rate of 8.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$41.70M+11.8%78.7%-21.9%-25.3%
    Dec 2024$37.30M+9.5%50.1%-46.1%-47.6%
    Dec 2023$34.07M+18.8%48.8%-66.6%-59.1%
    Dec 2022$28.67M+19.0%47.0%-64.8%-2.2%
    Dec 2021$24.10M+27.9%47.1%-104.6%-156.5%
    Dec 2020$18.85M-28.0%51.9%-51.0%-58.3%
    Dec 2019$26.18MN/A52.6%-57.0%-41.9%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$41.70M$37.30M$34.07M$28.67M$24.10M$18.85M$26.18M
    Cost of revenue$8.90M$18.61M$17.44M$15.19M$12.74M$9.07M$12.41M
    Gross profit$32.80M$18.70M$16.63M$13.49M$11.36M$9.78M$13.77M
    Research and development$3.72M$2.09M$77.00K$0$0$0$0
    Operating income-$9.15M-$17.21M-$22.68M-$18.58M-$25.20M-$9.61M-$14.92M
    Net income-$10.54M-$17.76M-$20.13M-$640.00K-$37.71M-$10.99M-$10.98M
    EBITDAN/A-$14.44M-$18.45M$934.00KN/A-$7.46M-$8.15M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$12.00M$10.08M$17.10M$6.99M$9.03M$8.59M$12.56M$9.01M$7.84M$7.90M$10.60M$8.90M
    Gross profit$9.59M$8.25M$16.23M$4.92M$6.36M$5.29M$7.29M$4.13M$3.50M$3.96M$5.23M$4.31M
    Operating income-$524.00K-$4.32M$6.76M-$6.28M-$5.08M-$4.55M-$1.71M-$4.96M-$5.07M-$5.47M-$3.87M-$4.62M
    Net income-$604.00K-$4.75M$5.64M-$6.65M-$5.32M-$4.20M-$1.40M-$5.67M-$257.00K-$10.44M$3.53M-$6.34M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $4.92M by $1.47M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$28.56M$22.10M$27.93M$50.88M$53.22M$24.14M$28.75M
    Current assets$18.08M$20.70M$23.07M$43.14M$46.42M$19.58M$23.47M
    Cash and equivalents$6.39M$5.91M$1.34M$17.21M$24.55M$8.08M$7.30M
    Total liabilities$18.08M$17.67M$23.14M$27.01M$41.88M$18.31M$58.93M
    Short-term debt$332.00K$548.00K$4.59M$498.00K$6.69MN/AN/A
    Long-term debt$4.59M$4.10MN/AN/AN/AN/A$38.20M
    Shareholder equity$10.48M$4.43M$4.79M$23.88M$11.34M$5.83M-$30.18M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$24.06M$24.79M$28.56M$15.41M$20.14M$16.59M$22.10M$18.52M$21.57M$24.57M$27.93M$34.10M
    Total liabilities$18.11M$18.72M$18.08M$18.00M$24.81M$16.12M$17.67M$12.99M$10.66M$29.99M$23.14M$33.07M
    Cash and equivalents$4.66M$6.32M$6.39M$3.42M$7.24M$1.78M$5.91M$2.87M$4.38M$3.82M$1.34M$3.42M
    Shareholder equity$5.96M$6.07M$10.48M-$2.58M-$4.67M$469.00K$4.43M$5.53M$10.91M-$5.42M$4.79M$1.04M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$13.36M-$10.27M-$24.89M-$16.20M-$26.71M-$12.37M-$37.68M
    Capital expenditures$2.00K$60.00K$5.00K$38.00K$11.00K$0$538.00K
    Free cash flow-$13.36M-$10.33M-$24.90M-$16.24M-$26.73M-$12.37M-$38.22M
    Investing cash flow$3.00M-$3.00K$619.00K-$5.16M-$11.00KN/A$25.39M
    Financing cash flow$10.85M$14.84M$8.41M$14.02M$43.19M$13.19M$16.40M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$1.66M-$70.00K-$2.38M-$3.82M-$3.04M-$4.12M-$1.02M-$1.21M-$4.72M-$3.33M-$8.87M-$2.00M
    Capital expenditures$0$5.00K$1.00K$1.00K$1.00K$3.00K$1.00K$50.00K$2.00K$57.00K$9.00K$0
    Free cash flow-$1.66M-$75.00K-$2.38M-$3.82M-$3.05M-$4.12M-$1.02M-$1.26M-$4.72M-$3.38M-$8.88M-$2.00M
    Last 12 quarters

    Frequently Asked Questions About BFRIW

    What is Biofrontera Inc. Warrants' annual revenue?

    Biofrontera Inc. Warrants reported revenue of $41.70M for the fiscal year ended Dec 31, 2025.

    How fast is Biofrontera Inc. Warrants' revenue growing?

    Revenue was up 11.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 13.3%.

    Is Biofrontera Inc. Warrants profitable?

    No. Biofrontera Inc. Warrants reported net income of -$10.54M for the fiscal year ended Dec 31, 2025, with a net margin of -25.3%.

    How much free cash flow does BFRIW generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.36M minus capital expenditures of $2.00K produced free cash flow of -$13.36M.

    How much debt does Biofrontera Inc. Warrants have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $4.59M, short-term debt of $332.00K and cash and equivalents of $6.39M.